Antithrombin ligands and candidate receptor genes were co-expressed in HEK293T cells, and the candidate receptors bound to the ligand were identified by immunoprecipitation. The research is ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

They exert their effect by binding to antithrombin, which inhibits both activated factor X and thrombin via a specific pentasaccharide sequence. This binding results in a conformational change in ...